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Background:  Latent  toxoplasmosis  always  has  the  risk  of  reactivation  leading  to  signiﬁ-
cant  sequelae.  The  available  medications,  for chronic  toxoplasmosis,  are  awfully  limited  by
resistance  of  Toxoplasma  cysts.  Therefore,  there  is  a growing  necessity  for novel  therapeutic
approaches.  Agents  increasing  cAMP  levels  and  downregulating  proinﬂammatory  cytokine
could inhibit  Toxoplasma  conversion  to  the bradyzoite  stage.  This study  explores  a poten-
tial immunomodulatory  effect  of  rolipram,  a PDE4  inhibitor,  on the  course  of  experimental
toxoplasmosis  and  links  this  role  to deterrence  of  the  resistant  chronic  phase  of  the  disease.
Materials and  methods:  Mice  infected  with  low  pathogenic  strain  of  Toxoplasma  gondii  were
treated with  rolipram  for three  weeks.  The  effect  of  rolipram  was  evaluated  through  tissue
injury  scoring,  brain  cyst  count,  speciﬁc  IgG  titers  as well  as TNF-,  IFN-  and  IL-12  assays.
Results:  Rolipram  was partially  able  to prevent  the progression  to chronic  toxoplasmosis.
Toxoplasma  brain  cyst  burden  showed  a 74%  reduction  while  Toxoplasma-induced  inﬂam-
matory  foci  per  liver  area  and  nucleated  cells  per  inﬂammatory  focus  were  signiﬁcantly
reduced:  57.14%  and  61.3%  respectively.  Signiﬁcant  reduction  of  TNF-  (84.6%),  IFN-
(76.7%)  and  IL-12  (71%)  levels  was  demonstrated  along  with  signiﬁcant  inhibition  of  anti-
Toxoplasma  antibody  response.
Conclusion:  Rolipram  efﬁciently  modulated  the  Toxoplasma-induced  immunological
changes  with  a consequent  remission  of  chronic  toxoplasmosis.  This  study  is  the  ﬁrst  to
report  the  utilization  of  PDE4  inhibitors  as  possible  immune  modulators  of  chronic  phase
of Toxoplasma  infection.
© 2015  Saudi  Society  of  Microscopes.  Published  by Elsevier  Ltd.  All  rights  reserved.1. IntroductionToxoplasmosis is a cosmopolitan infection caused by
Toxoplasma gondiii,  an obligatory intracellular parasite. It is
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2213-879X/© 2015 Saudi Society of Microscopes. Published by Elsevier Ltd. All riestimated that 30–50% of the world population are infected
with the parasite, representing one of the most prevalent
infections among humans [1]. Latent toxoplasmosis always
has the risk of reactivation, in immunocompromised
patients, leading to acute encephalitis [2] or relapsing
ophthalmitis in immunocompetents [3]. Current therapy
relies on agents that can suppress active infection with no
effect on the latent phase of the disease [4]. The available
medications are awfully limited by resistance of Toxo-
plasma cysts and drug toxicity to the children, pregnant
ghts reserved.
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omen and immunocompromised patients [5]. Interfer-
nce with the pathways mediating tachyzoite–bradyzoite
nterconversion is crucial for modulating the pathogenesis
f Toxoplasma infection.
Cyclic nucleotide phosphodiesterases (PDEs) are criti-
al modulators of cellular levels of cAMP catalyzing cyclic
ucleotide hydrolysis [6]. Agents causing high cAMP levels
ave been reported to inhibit Toxoplasma conversion to the
radyzoite stage [7]. PDE4 inhibitors could interfere with
achyzoite–bradyzoite interconversion due to suppression
f cytokines; TNF-, IFN- and IL-12, having pivotal roles
n this transition [8,9]. While proinﬂammatory cytokines,
specially IFN- and TNF-, are critical for an effective
hecking of Toxoplasma growth and dissemination, they are
amaging when overproduced [10]. Complete neutraliza-
ion or inhibition of pro-inﬂammatory cytokines could lead
o an exacerbated acute disease. Neutralization of IL-12 has
hown to result in an overwhelming Toxoplasma prolifera-
ion and a severe acute stage in infected mice [11].
This study represents an alternative approach for better
anagement of latent toxoplasmosis. The purpose of the
tudy was to explore a potential role of rolipram, a PDE4
nhibitor, in aborting the progression to chronic toxoplas-
osis. The roles played by pro-inﬂammatory cytokines to
ediate this progression were highlighted.
. Materials and methods
.1. Animals
Female Swiss albino mice, 6–8 weeks old and weight-
ng 25–30 g (from a local KAU university vendor) were
ept under standard laboratory conditions. The mice had
ree access to standard diet and water throughout the
xperiment. Animal experimentations were performed
n accordance with the Code of Ethics of EU Direc-
ive 2010/63/EU for animal experiments [12]. Mice were
ivided into three groups (10 mice each). An infection con-
rol group (GI) were challenged with T. gondii (KSU strain).
he second group (GII) received, day 7 post infection and for
hree weeks, 10 mg/kg/day rolipram (Sigma, St. Louis, MO,
SA) by oral gavage. A drug-control group (GIII) received
olipram (as in GII) without a parasitic challenge. A single
olipram concentration representing the highest but safe
herapeutic dosage [13], was used in the study.
.2. Parasitic challenge
Mice of GI and GII were challenged with intraperitoneal
i.p.) injection of 20 Toxoplasma tissue cysts in a total vol-
me  of 0.1 ml  sterile brain emulsion of a Swiss albino
ouse infected two months earlier. The low pathogenic,
yst-forming KSU strain of T. gondii (a generous gift from
in-shams Diagnostic and Research Unit, Cairo, Egypt) was
sed.
.3. Rolipram preparationRolipram was initially dissolved, at a concentration
f 1 mg/10 l DMSO. A ﬁnal concentration of 1 mg/ml
as reached by dilution with an appropriate volume ofy and Ultrastructure 3 (2015) 86–91 87
phosphate-buffered saline (PBS). The ﬁnal concentration of
the vehicle (DMSO) was 1%. Mice of relevant groups were
treated with rolipram as mentioned above.
2.4. Blood and tissue sampling
On day 14 post-infection (PI), 3 mice/group were anes-
thetized and then euthanized by cervical dislocation. Liver
excision and blood sampling were done using standard pro-
cedures. Blood sampling was  repeated at day-28 PI (after
completion of rolipram treatment), for the rest of mice
(7 mice/group). On day 50 PI, 7 mice/group were eutha-
nized and similar processes of blood sampling and brain
harvesting were performed.
Blood samples were centrifuged, sera were separated
and then stored at −80 ◦C for later analytical assays.
Recovered brains were immediately homogenized for cyst
counting. Liver samples were ﬁxed in buffered formalin
(10%) for histological examination.
2.5. Brain cyst counting
Isolated brains, from all mice groups (day-50 PI), were
crushed individually in a mortar. The grinded brain tissue
was dispersed in 2 ml  saline by passing it through needles
with decreasing gauge sizes. The number of cysts, per indi-
vidual brain, was then counted microscopically in 10 ml  of
the brain emulsion and the entire number of cysts per brain
was calculated.
2.6. Histopathological examination
Formol-ﬁxed liver samples, harvested on day-14 PI,
were immersed in parafﬁn, cut into 5 m-thickness sec-
tions and stained with hematoxylin and eosin. The liver
sections were assessed microscopically for inﬂammatory
foci and nucleated cells. Inﬂammatory foci, deﬁned as iso-
lated cluster of 6–60 nucleated cells, were quantiﬁed as
previously described [14]. They were counted, at a mag-
niﬁcation of ×100, in 8 mm2 surface area of liver tissue.
Nucleated cells/inﬂammatory focus were counted at a
×400 magniﬁcation.
2.7. Antibody assays
Dye test (DT) was performed on serum, recovered
from all remaining mice (7/group) at day-50 PI. A micro-
modiﬁed method of Sabin-Feldman assay was performed
[15]. In a microtiter plate, a mixture of 2 × 106 tachyzoites
in 50% accessory factor was  added to assigned volumes of
mice sera to get serial four-fold dilutions. Tachyzoites, of
RH strain, were freshly recovered by peritoneal lavage of
mice infected two  days earlier while accessory factor was a
Toxoplasma-negative serum checked for speciﬁc antibodies
in a previous dye test. After 1 h incubation at 37 ◦C, titers
were read as the sera dilutions showing 50% parasite killing.
End-points were determined, after the addition of methy-
lene blue, using a phase contrast microscopy. Titers ≥1/16
were considered positive.
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2.8. Cytokine assays
Commercially available ELISA kits for mouse cytokines
(R&D Systems, MN,  USA) were used to determine the levels
(pg/ml) of TNF-, IFN- and IL-12-P40 in mice sera col-
lected at day-14 and 28 PI. The assay was run in duplicates
following the manufacturer’s instructions. The lower sensi-
tivity limits of TNF-, IFN- and IL-12 assays were 5 pg/ml,
2 pg/ml and 7.8 pg/ml respectively. Cytokine levels below
the assay’s threshold of detection were assigned hypothet-
ical values of the lower limit of sensitivity of each assay.
2.9. Statistical analysis
The results are demonstrated as mean ± SD. Several
comparisons, related to different variables among all
groups, were made using SPSS software, version 18 (SPSS
Inc., Chicago, IL). Two-tailed Student (t-) test was used and
p ≤ 0.05 was considered statistically signiﬁcant.
3. Results
3.1. Scored liver pathology
Toxoplasma-infected mice treated with rolipram
developed signiﬁcantly fewer inﬂammatory foci than
Toxoplasma-infected group. Number of cells per focus
signiﬁcantly regressed and the inﬂammatory foci became
smaller and less frequent. The inﬂammatory foci/liver area
were decreased to less than one-half (57% reduction), and
the numbers of nucleated cells/inﬂammatory focus were
decreased by 61%, in rolipram-treated mice compared to
infected control mice (Fig. 1).
3.2. Brain cyst burden
The results showed also a mean suppression of 74%
of T. gondii brain cyst formation under the inﬂuence of
rolipram treatment. The number of brain tissue cysts, has
been signiﬁcantly (p < 0.001) decreased, almost four fold,
in rolipram-treated mice compared to non-treated ones
(Fig. 2A).
3.3. Anti-Toxoplasma antibody
The reduction in parasitic load and tissue inﬂammatory
reactions was reﬂected in a highly signiﬁcant (p < 0.001)
reduction of anti-Toxoplasma antibody titers (Fig. 2B). The
results showed a 61% suppression of antibody response to
T. gondii infection mediated by rolipram treatment.
3.4. Cytokines proﬁle
Compared to that of the infection control, TNF- only
showed a highly signiﬁcant (p < 0.001) reduction while a
just signiﬁcant (p < 0.05) suppression of both IFN- and
IL-12 levels was demonstrated at day-14 PI (Fig. 3A). The
cytokine pattern was considerably different at day-28 PI
(Fig. 3B), where a highly signiﬁcant (p < 0.001) reduction of
all tested cytokines, in rolipram-treated infected mice, was
demonstrated. Percentages of reduction as high as 84.6%,py and Ultrastructure 3 (2015) 86–91
76.7% and 71% were demonstrated for TNF-, IFN- and
IL-12 respectively.
4. Discussion
We  have explored the immunomodulatory role of
rolipram, a selective PDE4 inhibitor, in a murine model
of chronic toxoplasmosis. The current results comple-
ment and explain a previous report [16] conﬁrming that
rolipram, is both necessary and sufﬁcient to mitigate the
classic immunological and pathological patterns of Toxo-
plasma infection.
Many reasons were behind our choice to use rolipram.
While a selective PDE4 inhibitor, rolipram inhibits all PDE4
subtypes with comparable potencies [17]. Rolipram has a
highly selective potency in brain tissue, where PDE4 are
mainly found [18], and where T. gondii prefers to establish
its chronic state of infection [19].
Two  main concerns raised while applying a PDE4
inhibitor to modulate T. gondii infection. First, is an
expected exacerbation of the acute stage which could lead
to a lethal outcome. The second concern was  a possible
reactivation of the chronic stage leading to a fatal toxo-
plasmic encephalitis. PDE4 inhibitors have a suppressant
effect on pro-inﬂammatory cytokines [8] which have crit-
ical roles in both resisting acute infection and stabilizing
the chronic stage of toxoplasmosis [9]. Previous studies
reported an overwhelming proliferation of the parasite
and a severe acute T. gondii infection in mice on neu-
tralizing IL-12 and other proinﬂammatory cytokines [11].
Other reports showed that neutralization of TNF- in a
chronically infected mice led to reactivation of chronic
toxoplasmosis and a fatal outcome of the disease [20]. Addi-
tionally, mice deﬁcient in certain TNF receptors developed
fatal toxoplasmic encephalitis [21]. However both concerns
did not come true in our study. We suggest that TNF-, IFN-
 and IL-12 levels, while reduced, helped rolipram-treated
mice to avoid an exacerbated acute phase. Conversely, it is
possible that their levels were not low enough to deter the
transition to a chronic but interestingly incomplete state.
The results interestingly showed that rolipram efﬁ-
ciently induced a remission of chronic toxoplasmic lesions,
with a signiﬁcant reduction of liver pathology and brain
cysts. This ﬁnding is explicable because potent cAMP-
mediated anti-inﬂammatory effects of rolipram, have
been demonstrated in various cellular and animal models
[22]. Rolipram opposed the TNF--induced loss in barrier
integrity of the corneal endothelium [23].
Rolipram-induced mitigation of liver injury, shown in
this study, is also explainable and complementary to what
we have reported earlier [16]. It could be, in part, due
to signiﬁcant regression in TNF- release with subse-
quent prevention of its tissue damaging effect. However,
the observed marked reduction of IFN- and IL-12 levels
could have a share in this effect. Interferon- and IL-12
interplay with TNF- to mediate Toxoplasma-associated
pathology. Thus their observed down-regulation might
have mediated the anti-inﬂammatory action of rolipram.
Furthermore, IFN- is a critical TNF- sensitivity prim-
ing factor. Appropriate priming of hepatocytes with IFN-,
makes them more susceptible to TNF- damaging effect
M.A. Aﬁﬁ, M.W. Al-Rabia / Journal of Microscopy and Ultrastructure 3 (2015) 86–91 89
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aig. 1. Scored liver pathology to show the modulatory role of rolipram in
he  mean of that counted in a liver tissue area 1 × 8 mm2. Number of nucl
ean  of three mice. **Highly signiﬁcant difference, p < 0.001.
24]. Rolipram suppresses nitric oxide production indepen-
ent of its inhibitory effect on TNF- or IL-12 secretion [25]
uggesting a role for the anti-oxidant action of rolipram in
he mitigation of the observed liver pathology.
ig. 2. Effect of rolipram on T. gondii-infected mice at day-50 PI. Each number re
f  brain cysts shown is the calculated mean of an overall cyst burden in mice bra
nti-Toxoplasma antibodies assayed by DT in sera of infected mice. **Highly signiii-infected mice (day-14 PI). Number of inﬂammatory foci (IF) shown is
lls (NCs) shown per IF is the mean of 20 foci. Each number represents the
Investigation of the individual role of PDE4 subtypes
was beyond the scope of our study. However, we  speculate
that rolipram inhibition of phosphodiestrase B-subtype
(PDE4B) might mediate the beneﬁcial effects observed in
presents the mean of seven mice. (A) Brain tissue cyst burden. Number
ins counted in 10 ml  brain emulsion per mouse. (B) Mean titers of total
ﬁcant difference, p < 0.001.
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gondii-i
ce, p < 0
was  introduced. Our ﬁndings are the ﬁrst to link the anti-Fig. 3. Effect of rolipram on TNF-, IFN- and IL-12 (pg/ml) release in T. 
for  3–7 mice. *Signiﬁcant difference, p < 0.05, **highly signiﬁcant differen
this study. PDE4B was previously considered to be essen-
tial for lipopolysaccharide-activated TNF- responses
[16].
Many factors might be involved in partial resolve of
pathology and incomplete inhibition of the chronic phase.
However, we cannot exclude that the rolipram has just
achieved a partial block of TNF-, IFN- or IL-12 release.
We think that rolipram was able to keep cytokines at low
levels enough to resist the infection while still able to inﬂict
a form of tissue injury that is considerably mitigated.
Parasite’s strain variability might have a share in the
pathology-mitigating effects of rolipram, demonstrated
in our study. Low pathogenic, cyst-forming strains of T.
gondii are particularly suitable for cAMP manipulation by
PDE4 inhibitors. This ﬁnding was not observed in viru-
lent, poorly differentiating strains [7]. Therefore, it is likely
to observe different treatment responses with different
infecting strains of the parasite.
Despite its potency as an anti-inﬂammatory drug, pre-
vious clinical studies reported undesirable adverse effectsnfected mice at day-14 (A) and day-28 (B) PI. Numbers represent means
.001.
of rolipram mainly severe nausea and vomiting [26]. The
intolerable emetic action of rolipram might be due to
inhibition of the D-subtype (PDE4D) [27]. Therefore, a
selective PDE4B inhibitor, sparing PDE4D, would serve as
better anti-Toxoplasma drug with no emetic action. More-
over, considering the unmet need for new therapies and
the interest in a short course of treatment, the necessity
for strict selectivity might be diminished if the drug was
efﬁcacious in a shorter course time compared to current
medications.
Conclusion
A novel approach, to halt transition to the drug-
resistant chronic toxoplasmosis rather than treating it,inﬂammatory action of PDE4 inhibitors to the modulation
of the course of toxoplasmosis presenting rolipram as a
useful modulator of Toxoplasma-induced tissue injury.
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